← back to search

Nora Cazzagon

IRCCS Humanitas Research Hospital · IT
Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Diseases and Immunity, Liver Disease Diagnosis and Treatment, Gallbladder and Bile Duct Disorders, and Pediatric Hepatobiliary Diseases and Treatments.
h-index
37
citations
5,607
works
230
NIH funding
primary concept
Medicine
email

Recent publications

Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
2026cited by 2position: contributordoi
Biochemical Response Criteria Predict Transplant-Free Survival Across Disease Stages in Primary Biliary Cholangitis:Findings From the FiOCA Study
Research at the University of Copenhagen (University of Copenhagen) 2026cited by 0position: middledoi
Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy.
2026cited by 0position: contributordoi
Long-term add-on fibrate therapy in Primary Sclerosing Cholangitis: Safety, biochemical response, and disease progression
Digestive and Liver Disease 2026cited by 0position: contributordoi
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial
Journal of Hepatology 2025cited by 15position: middledoi
In-Hospital Screening Campaign Against Hepatitis C Could Be Effective for Identifying More Patients Who Still Need Treatment.
2025cited by 2position: contributordoi
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study
Liver International 2025cited by 1position: middledoi
Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world
JHEP Reports 2025cited by 1position: middledoi
Prevalence of Celiac Disease in Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.
2025cited by 1position: contributordoi
Primary biliary cholangitis (PBC): evolving approaches and expert perspectives
Expert Review of Gastroenterology & Hepatology 2025cited by 0position: middledoi
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study.
2025cited by 0position: contributordoi
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
2024cited by 42position: contributordoi
Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
Clinical Gastroenterology and Hepatology 2024cited by 28position: middledoi
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
JHEP Reports 2024cited by 13position: middledoi
Primary Sclerosing Cholangitis: Diagnostic Criteria
Tomography 2024cited by 13position: firstdoi
Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
JHEP Reports 2024cited by 12position: contributordoi
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis
Clinical Gastroenterology and Hepatology 2024cited by 9position: middledoi
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.
2024cited by 7position: contributordoi
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis
Clinical Gastroenterology and Hepatology 2024cited by 4position: middledoi
Liver transplantation for Wilson disease: Current knowledge and future perspectives.
2024cited by 4position: contributordoi
Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis.
2024cited by 4position: contributordoi
Longer transplant-free and liver-related event-free survival in obeticholic acid-treated patients with primary biliary cholangitis compared to external controls from two large real-world cohorts
Digestive and Liver Disease 2024cited by 3position: middledoi
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Hepatology 2023cited by 74position: middledoi
Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival
Liver International 2023cited by 29position: middledoi
Patient-reported quality of care in primary sclerosing cholangitis.
2023cited by 7position: contributordoi
The unhealthy lifestyle in primary biliary cholangitis: An enemy to fight.
2023cited by 2position: contributordoi
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group
Journal of Hepatology 2022cited by 168position: middledoi
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis
Journal of Hepatology 2022cited by 109position: middledoi
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls
Gastroenterology 2022cited by 95position: middledoi
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.
2022cited by 78position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Annarosa Floreani · Ospedale Sacro Cuore Don Calabria25 papers (2012–2026) · 14 papers (2019–2026)Marco Carbone · Istituti di Ricovero e Cura a Carattere Scientifico12 papers (2018–2025)I. Franceschet · University of Padua10 papers (2013–2018)Francesco Paolo Russo · National Research Council10 papers (2019–2025)Christophe Corpechot · University Health Network8 papers (2019–2022)Marco Marzioni · University of Bologna8 papers (2021–2025)Albert Parés · Universitat Autònoma de Barcelona7 papers (2014–2021)Xavier Verhelst · Centre de Recherche sur l'Inflammation7 papers (2019–2024)Cristina Rigamonti · University of Bologna7 papers (2020–2025) · 6 papers (2020–2025)Samantha Sarcognato · AULSS 2 Marca Trevigiana6 papers (2021–2024)Pietro Invernizzi · University Health Network5 papers (2020–2025)Maria Guido · University of Padua5 papers (2021–2022)Pietro Invernizzi · University Health Network5 papers (2015–2025)Lisa Perini · University of Padua4 papers (2014–2019)Ana Lleo · Istituti di Ricovero e Cura a Carattere Scientifico4 papers (2021–2024)Annika Bergquist · Integrated Cardio Metabolic Centre4 papers (2020–2026) · 4 papers (2020–2022)Tony Bruns · Friedrich Schiller University Jena4 papers (2020–2024)